Lung adenocarcinoma associated with familial adenomatous polyposis. Clear cell carcinoma with beta-catenin accumulation accompanied by atypical adenomatous hyperplasia

Overcoming the systemic administration of chemotherapy to reduce drug toxicity and the application of personalised medicine are two of the major challenges in the treatment of cancer. To this aim,...

Download Full-text

Multiomic Analysis of Cereblon Expression and Its Prognostic Value in Kidney Renal Clear Cell Carcinoma, Lung Adenocarcinoma, and Skin Cutaneous Melanoma

Journal of Personalized Medicine ◽

10.3390/jpm11040263 ◽

2021 ◽

Vol 11 (4) ◽

pp. 263

Author(s):

Hyo Jae Shin ◽

Kyung Jin Lee ◽

Minchan Gil

Keyword(s):

Lung Adenocarcinoma ◽

Cell Carcinoma ◽

Cancer Progression ◽

Cutaneous Melanoma ◽

Prognostic Value ◽

Clear Cell ◽

Clear Cell Carcinoma ◽

Renal Clear Cell Carcinoma ◽

Clinical Value ◽

Cancer Types

Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex that plays crucial roles in various cellular processes. However, no systematic studies on the expression and functions of CRBN in solid tumors have been conducted to date. Here, we analyzed CRBN expression and its clinical value using several bioinformatic databases. CRBN mRNA expression was downregulated in various cancer types compared to normal cells. Survival analysis demonstrated that overall survival was significantly positively correlated with CRBN expression in some cancer types including lung adenocarcinoma (LUAD), kidney renal clear cell carcinoma (KIRC), and skin cutaneous melanoma (SKCM). CRBN expression was downregulated regardless of clinicopathological characteristics in LUAD and KIRC. Analysis of genes that are commonly correlated with CRBN expression among KIRC, LUAD, and SKCM samples elucidated the potential CRBN-associated mechanisms of cancer progression. Overall, this study revealed the prognostic value of CRBN and its potential associated mechanisms, which may facilitate the development of anti-cancer therapeutic agents.

Download Full-text

Association of beta-catenin and CD44 in the development of renal cell carcinoma

Urologia Journal ◽

10.1177/0391560320980672 ◽

2020 ◽

pp. 039156032098067

Author(s):

Akash Agrawal ◽

Chhanda Datta ◽

Chinmay Kumar Panda ◽

Dilip Kumar Pal

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Clear Cell Carcinoma ◽

Beta Catenin ◽

Prognostic Information ◽

Altered Expression ◽

Primary Renal Cell Carcinoma ◽

Promising Target

Introduction and objective: Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers. Approximately 25%–30% of patients present with metastatic disease at the time of diagnosis, and metastatic RCC is a treatment-resistant malignancy. Altered expression of cell adhesion molecules such as CD44 on tumor cells suggests a pathogenetic mechanism for tumor metastasis and may provide prognostic information for particular tumors. These cell matrix interactions of CD44 play a role in tumor cell invasion and metastasis. The Wnt/beta-catenin pathway turned out to be a promising target as it is involved in the regulation of cell proliferation, differentiation and apoptosis induction. Method: In this study, the expression of beta-catenin and CD44 was analyzed in primary renal cell carcinoma (RCC) samples to understand their association with development of the disease. For this purpose, immunohistochemical expression analysis of beta-catenin and CD44 was performed in 30 primary RCC histological samples and normal kidney tissues in different subtypes at different clinical stages of Indian patients (year: 2017–2019). Result: Most of the patients who presented were diagnosed as clear cell carcinoma and it was observed that expression of CD44 was high in patients with high stage tumors. Also beta-catenin was increased in advanced grade tumors, but there was insignificant correlation between high expression of molecules and survival or recurrence of disease. Conclusion: Both cd44 and beta-catenin activation was noted in patients with clear cell carcinoma, more in advanced tumors. Both can be promising targets for treatment in clear cell RCCs.

Download Full-text

Primary Peritoneal Clear Cell Carcinoma

10.32388/b7gpw9 ◽

2020 ◽

Author(s):

Keyword(s):

Cell Carcinoma ◽

Clear Cell ◽

Clear Cell Carcinoma

Download Full-text

Delayed Pancreatic Metastasis of Renal Clear Cell Carcinoma

Acta Chirurgica Latviensis ◽

10.2478/chilat-2014-0016 ◽

2013 ◽

Vol 13 (2) ◽

pp. 79-80

Author(s):

Zane Simtniece ◽

Gatis Kirsakmens ◽

Ilze Strumfa ◽

Andrejs Vanags ◽

Maris Pavars ◽

...

Keyword(s):

Abdominal Pain ◽

Surgical Treatment ◽

Cell Carcinoma ◽

Clear Cell ◽

Clear Cell Carcinoma ◽

Primary Tumour ◽

Renal Clear Cell Carcinoma ◽

Pancreatic Metastasis ◽

Distal Pancreatic Resection

Abstract Here, we report surgical treatment of a patient presenting with pancreatic metastasis (MTS) of renal clear cell carcinoma (RCC) 11 years after nephrectomy. RCC is one of few cancers that metastasise in pancreas. Jaundice, abdominal pain or gastrointestinal bleeding can develop; however, asymptomatic MTS can be discovered by follow-up after removal of the primary tumour. The patient, 67-year-old female was radiologically diagnosed with a clinically silent mass in the pancreatic body and underwent distal pancreatic resection. The postoperative period was smooth. Four months after the surgery, there were no signs of disease progression.

Download Full-text